MiR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor

Cancer Cell International

Volumn 13, Issue 1, 2013, Pages

  Iida, Keiichiro ^a   Fukushi, Jun Ichi ^a   Matsumoto, Yoshihiro ^a   Oda, Yoshinao ^a   Takahashi, Yusuke ^a   Fujiwara, Toshifumi ^a   Fujiwara Okada, Yuko ^a   Hatano, Mihoko ^a   Nabashima, Akira ^a   Kamura, Satoshi ^a   Iwamoto, Yukihide ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Bak; Chemoresistance; Ewing sarcoma primitive neuroectodermal tumor; miR 125b; p53

Indexed keywords

DOXORUBICIN; ETOPOSIDE; MAFOSFAMIDE; MICRORNA 125B; PROTEIN BAK; PROTEIN P53; VINCRISTINE;

APOPTOSIS; ARTICLE; ASSAY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL SURVIVAL; CHEMORESISTANCE; CHEMOSENSITIVITY ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; EWING SARCOMA; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROECTODERM TUMOR; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA EXTRACTION; RNA SEQUENCE; UPREGULATION; WESTERN BLOTTING;

EID: 84874449515     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-13-21     Document Type: Article

References (53)

1. Iwamoto Y. Diagnosis and treatment of Ewing's sarcoma. Jpn J Clin Oncol 2007, 37:79-89. 10.1093/jjco/hyl142, 17272319.
2. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Miser JS. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003, 348:694-701. 10.1056/NEJMoa020890, 12594313.
3. Meyers PA, Krailo MD, Ladanyi M, Chan KW, Sailer SL, Dickman PS, Baker DL, Davis JH, Gerbing RB, Grovas A, Herzog CE, Lindsley KL, Liu-Mares W, Nachman JB, Sieger L, Wadman J, Gorlick RG. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 2001, 19:2812-2820.
4. Miser JS, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Grier HE. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide-a Children's cancer group and pediatric oncology group study. J Clin Oncol 2004, 22:2873-2876. 10.1200/JCO.2004.01.041, 15254055.
5. Rodriguez-Galindo C, Billups CA, Kun LE, Rao BN, Pratt CB, Merchant TE, Santana VM, Pappo AS. Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer 2002, 94:561-569. 10.1002/cncr.10192, 11900241.
6. Shankar AG, Ashley S, Craft AW, Pinkerton CR. Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol 2003, 40:141-147. 10.1002/mpo.10248, 12518341.
7. Fodale V, Pierobon M, Liotta L, Petricoin E. Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance?. Cancer J 2011, 17:89-95. 10.1097/PPO.0b013e318212dd3d, 21427552.
8. Scotlandi K, Avnet S, Benini S, Manara MC, Serra M, Cerisano V, Perdichizzi S, Lollini PL, De Giovanni C, Landuzzi L, Picci P. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int J Cancer 2002, 101:11-16. 10.1002/ijc.10537, 12209582.
9. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, Croci S, Perdichizzi S, Zambelli D, Serra M, Garcia-Echeverria C, Hofmann F, Picci P. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005, 65:3868-3876. 10.1158/0008-5472.CAN-04-3192, 15867386.
10. Gonzalez I, Andreu EJ, Panizo A, Inoges S, Fontalba A, Fernandez-Luna JL, Gaboli M, Sierrasesumaga L, Martin-Algarra S, Pardo J, Prosper F, de Alava E. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res 2004, 10:751-761. 10.1158/1078-0432.CCR-0778-03, 14760098.
11. Scotlandi K, Manara MC, Strammiello R, Landuzzi L, Benini S, Perdichizzi S, Serra M, Astolfi A, Nicoletti G, Lollini PL, Bertoni F, Nanni P, Picci P. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol 2003, 21:1952-1960. 10.1200/JCO.2003.11.111, 12743148.
12. Scotlandi K, Baldini N, Cerisano V, Manara MC, Benini S, Serra M, Lollini PL, Nanni P, Nicoletti G, Bernard G, Bernard A, Picci P. CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res 2000, 60:5134-5142.
13. Jiang X, Gwye Y, Russell D, Cao C, Douglas D, Hung L, Kovar H, Triche TJ, Lawlor ER. CD133 expression in chemo-resistant Ewing sarcoma cells. BMC Cancer 2010, 10:116. 10.1186/1471-2407-10-116, 2851692, 20346143.
14. Ganjavi H, Gee M, Narendran A, Freedman MH, Malkin D. Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther 2005, 12:397-406. 10.1038/sj.cgt.7700798, 15618970.
15. Nakamura T, Tanaka K, Matsunobu T, Okada T, Nakatani F, Sakimura R, Hanada M, Iwamoto Y. The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells. Int J Oncol 2007, 31:803-811.
16. Okada T, Tanaka K, Nakatani F, Sakimura R, Matsunobu T, Li X, Hanada M, Nakamura T, Oda Y, Tsuneyoshi M, Iwamoto Y. Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells. Int J Cancer 2006, 118:90-97. 10.1002/ijc.21297, 16049968.
17. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297. 10.1016/S0092-8674(04)00045-5, 14744438.
18. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
19. Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther 2010, 17:523-531. 10.1038/cgt.2010.18, 20467450.
20. Nakatani F, Ferracin M, Manara MC, Ventura S, Del Monaco V, Ferrari S, Alberghini M, Grilli A, Knuutila S, Schaefer KL, Mattia G, Negrini M, Picci P, Serra M, Scotlandi K. miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemosensitivity and malignancy. J Pathol 2011, 226:796-805.
21. Skladanowski A, Konopa J. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem Pharmacol 1993, 46:375-382. 10.1016/0006-2952(93)90512-U, 7688510.
22. Kumar M, Lu Z, Takwi AA, Chen W, Callander NS, Ramos KS, Young KH, Li Y. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 2011, 30:843-853. 10.1038/onc.2010.457, 3021102, 20935678.
23. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, Tepper CG, Evans CP, Kung HJ, deVere White RW. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA 2007, 104:19983-19988. 10.1073/pnas.0706641104, 2148409, 18056640.
24. Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, White RW. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate 2011, 71:538-549. 10.1002/pros.21270, 3017658, 20886540.
25. Zeng CW, Zhang XJ, Lin KY, Ye H, Feng SY, Zhang H, Chen YQ. Camptothecin Induces Apoptosis in Cancer Cells via miR-125b Mediated Mitochondrial Pathways. Mol Pharmacol 2012, 81:578-586. 10.1124/mol.111.076794, 22252650.
26. Panaretakis T, Pokrovskaja K, Shoshan MC, Grander D. Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J Biol Chem 2002, 277:44317-44326. 10.1074/jbc.M205273200, 12193597.
27. Biedler JL, Helson L, Spengler BA. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 1973, 33:2643-2652.
28. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol 2010, 11:184-192. 10.1016/S1470-2045(09)70286-4, 20152770.
29. Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009, 124:511-515. 10.1002/ijc.24064, 19003982.
30. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong L, Liu J, Fan D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008, 123:372-379. 10.1002/ijc.23501, 18449891.
31. Zhu W, Shan X, Wang T, Shu Y, Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010, 127:2520-2529. 10.1002/ijc.25260, 20162574.
32. Chalfie M, Horvitz HR, Sulston JE. Mutations that lead to reiterations in the cell lineages of C. elegans. Cell 1981, 24:59-69. 10.1016/0092-8674(81)90501-8, 7237544.
33. Guo S, Lu J, Schlanger R, Zhang H, Wang JY, Fox MC, Purton LE, Fleming HH, Cobb B, Merkenschlager M, Golub TR, Scadden DT. MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci USA 2010, 107:14229-14234. 10.1073/pnas.0913574107, 2922532, 20616003.
34. Rybak A, Fuchs H, Smirnova L, Brandt C, Pohl EE, Nitsch R, Wulczyn FG. A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nat Cell Biol 2008, 10:987-993. 10.1038/ncb1759, 18604195.
35. Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, Huang MY, Hou JH, Wu QL, Zeng MS, Huang WL, Zeng YX, Shao JY. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res 2011, 71:3552-3562. 10.1158/0008-5472.CAN-10-2435, 21444677.
36. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007, 282:1479-1486.
37. Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V, Lodish HF, Lim B. MicroRNA-125b is a novel negative regulator of p53. Genes Dev 2009, 23:862-876. 10.1101/gad.1767609, 2666337, 19293287.
38. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65:7065-7070. 10.1158/0008-5472.CAN-05-1783, 16103053.
39. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E, Liu CG, Petrocca F, Troncone G, Calin GA, Scarpa A, Colato C, Tallini G, Santoro M, Croce CM, Fusco A. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 2007, 26:7590-7595. 10.1038/sj.onc.1210564, 17563749.
40. Li W, Xie L, He X, Li J, Tu K, Wei L, Wu J, Guo Y, Ma X, Zhang P, Pan Z, Hu X, Zhao Y, Xie H, Jiang G, Chen T, Wang J, Zheng S, Cheng J, Wan D, Yang S, Li Y, Gu J. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 2008, 123:1616-1622. 10.1002/ijc.23693, 18649363.
41. Willimott S, Wagner SD. miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells. J Biol Chem 2012, 287:2608-2617. 10.1074/jbc.M111.285718, 3268420, 22139839.
42. Jiang F, Liu T, He Y, Yan Q, Chen X, Wang H, Wan X. MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo. BMC Cancer 2011, 11:425. 10.1186/1471-2407-11-425, 3210504, 21970405.
43. Nishida N, Yokobori T, Mimori K, Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y, Kuwano H, Mori M. MicroRNA miR-125b is a prognostic marker in human colorectal cancer. Int J Oncol 2011, 38:1437-1443.
44. Kovar H, Auinger A, Jug G, Aryee D, Zoubek A, Salzer-Kuntschik M, Gadner H. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 1993, 8:2683-2690.
45. Ban J, Bennani-Baiti IM, Kauer M, Schaefer KL, Poremba C, Jug G, Schwentner R, Smrzka O, Muehlbacher K, Aryee DN, Kovar H. EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Cancer Res 2008, 68:7100-7109. 10.1158/0008-5472.CAN-07-6145, 18757425.
46. Li Y, Tanaka K, Fan X, Nakatani F, Li X, Nakamura T, Takasaki M, Yamamoto S, Iwamoto Y. Inhibition of the transcriptional function of p53 by EWS-Fli1 chimeric protein in Ewing Family Tumors. Cancer Lett 2010, 294:57-65. 10.1016/j.canlet.2010.01.022, 20153576.
47. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, Xiong W, Li G, Lu J, Fodstad O, Riker AI, Tan M. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 2010, 285:21496-21507. 10.1074/jbc.M109.083337, 2898411, 20460378.
48. Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 2004, 6:443-450. 10.1038/ncb1123, 15077116.
49. Svoboda M, Izakovicova Holla L, Sefr R, Vrtkova I, Kocakova I, Tichy B, Dvorak J. Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer. Int J Oncol 2008, 33:541-547.
50. Li J, Smyth P, Flavin R, Cahill S, Denning K, Aherne S, Guenther SM, O'Leary JJ, Sheils O. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol 2007, 7:36. 10.1186/1472-6750-7-36, 1914054, 17603869.
51. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, Ju J. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007, 13:1668-1674. 10.1261/rna.642907, 1986820, 17698639.
52. Kamura S, Matsumoto Y, Fukushi JI, Fujiwara T, Iida K, Okada Y, Iwamoto Y. Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway. Br J Cancer 2010, 103:370-381. 10.1038/sj.bjc.6605775, 2920026, 20606682.
53. Fujiwara T, Fukushi J, Yamamoto S, Matsumoto Y, Setsu N, Oda Y, Yamada H, Okada S, Watari K, Ono M, Kuwano M, Kamura S, Iida K, Okada Y, Koga M, Iwamoto Y. Macrophage infiltration predicts a poor prognosis for human ewing sarcoma. Am J Pathol 2011, 179:1157-1170. 10.1016/j.ajpath.2011.05.034, 3157220, 21771572.